Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Tables)

v3.24.1.1.u2
Note 3 - Revenue (Tables)
3 Months Ended
Mar. 31, 2024
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended March 31,

 
   

2024

   

2023

 

Pfizer

  $ 6     $ 1,423  

AstraZeneca

          434  

Servier

    47       (74 )

Genentech

          153  

Total Revenue

  $ 53     $ 1,936  
Revenue From Contract With Customer, Milestone Payments [Table Text Block]
   

Research, Development, Regulatory & Commercial Milestones

   

Sales Milestones

 

Pfizer

  $ 759     $ 450  

Servier

    105       97  

Boston Pharmaceuticals

    85       265  

Total potential milestone payments

  $ 949     $ 812